NCT05929456RecruitingPhase 1
MIRROR; Multispectral and bimodal fluorescent guided surgery (FGS) of high-grade glioma for refining margin assessment: A phase 1 dose finding study using Cetuximab-IRDye800CW- combined with 5-ALA
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 22 Aug 2024
- Start date
- 31 Mar 2023
- Lead sponsor
- Universitair Medisch Centrum Groningen
- Diseases
- Glioblastoma
- NCT number
- NCT05929456
- EU CT number
- 2024-513392-40-01
- EudraCT number
- 2022-002666-32
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 21
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UMCG Coordinator of this site? Confirm its status | Groningen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.